Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID- 19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.

Automated summary

The combination of baricitinib and hydroxychloroquine treatment in moderate-severe COVID-19 patients showed promising results in a retrospective study, suggesting the need for further investigation in randomized controlled trials to validate its efficacy.